Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis.
(2013) In Journal of Clinical Oncology 31(18). p.130-2303- Abstract
- PURPOSEThe LIVESTRONG Young Adult Alliance has conducted a meta-analysis of individual patient data from prospective neoadjuvant chemotherapy osteosarcoma studies and registries to examine the relationships of sex, age, and toxicity on survival. PATIENTS AND METHODSSuitable data sets were identified by a survey of published data reported in PubMed. The final pooled data set comprised 4,838 patients from five international cooperative groups.ResultsAfter accounting for important variables known at study entry such as tumor location and histology, females experienced higher overall survival rates than males (P = .005) and children fared better than adolescents and adults (P = .002). Multivariate landmark analysis following surgery indicated... (More)
- PURPOSEThe LIVESTRONG Young Adult Alliance has conducted a meta-analysis of individual patient data from prospective neoadjuvant chemotherapy osteosarcoma studies and registries to examine the relationships of sex, age, and toxicity on survival. PATIENTS AND METHODSSuitable data sets were identified by a survey of published data reported in PubMed. The final pooled data set comprised 4,838 patients from five international cooperative groups.ResultsAfter accounting for important variables known at study entry such as tumor location and histology, females experienced higher overall survival rates than males (P = .005) and children fared better than adolescents and adults (P = .002). Multivariate landmark analysis following surgery indicated that a higher rate of chemotherapy-induced tumor necrosis was associated with longer survival (P < .001), as was female sex (P = .004) and the incidence of grade 3 or 4 mucositis (P = .03). Age group was not statistically significant in this landmark analysis (P = .12). Females reported higher rates of grade 3 or 4 thrombocytopenia relative to males (P < .001). Children reported the highest rates of grade 3 or 4 neutropenia (P < .001) and thrombocytopenia (P < .001). The achievement of good tumor necrosis was higher for females than for males (P = .002) and for children than for adults (P < .001). CONCLUSIONThese results suggest fundamental differences in the way chemotherapy is handled by females compared with males and by children compared with older populations. These differences may influence survival in a disease in which chemotherapy is critical to overall outcomes. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3804510
- author
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Clinical Oncology
- volume
- 31
- issue
- 18
- pages
- 130 - 2303
- publisher
- American Society of Clinical Oncology
- external identifiers
-
- wos:000320446700016
- pmid:23669227
- scopus:84882932037
- pmid:23669227
- ISSN
- 1527-7755
- DOI
- 10.1200/JCO.2012.43.8598
- language
- English
- LU publication?
- yes
- id
- e460eca2-defa-4057-a711-e2b29f05bceb (old id 3804510)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23669227?dopt=Abstract
- date added to LUP
- 2016-04-01 10:07:02
- date last changed
- 2022-04-19 22:39:34
@article{e460eca2-defa-4057-a711-e2b29f05bceb, abstract = {{PURPOSEThe LIVESTRONG Young Adult Alliance has conducted a meta-analysis of individual patient data from prospective neoadjuvant chemotherapy osteosarcoma studies and registries to examine the relationships of sex, age, and toxicity on survival. PATIENTS AND METHODSSuitable data sets were identified by a survey of published data reported in PubMed. The final pooled data set comprised 4,838 patients from five international cooperative groups.ResultsAfter accounting for important variables known at study entry such as tumor location and histology, females experienced higher overall survival rates than males (P = .005) and children fared better than adolescents and adults (P = .002). Multivariate landmark analysis following surgery indicated that a higher rate of chemotherapy-induced tumor necrosis was associated with longer survival (P < .001), as was female sex (P = .004) and the incidence of grade 3 or 4 mucositis (P = .03). Age group was not statistically significant in this landmark analysis (P = .12). Females reported higher rates of grade 3 or 4 thrombocytopenia relative to males (P < .001). Children reported the highest rates of grade 3 or 4 neutropenia (P < .001) and thrombocytopenia (P < .001). The achievement of good tumor necrosis was higher for females than for males (P = .002) and for children than for adults (P < .001). CONCLUSIONThese results suggest fundamental differences in the way chemotherapy is handled by females compared with males and by children compared with older populations. These differences may influence survival in a disease in which chemotherapy is critical to overall outcomes.}}, author = {{Collins, Marnie and Wilhelm, Miriam and Conyers, Rachel and Herschtal, Alan and Whelan, Jeremy and Bielack, Stefan and Kager, Leo and Kühne, Thomas and Sydes, Matthew and Gelderblom, Hans and Ferrari, Stefano and Picci, Piero and Smeland, Sigbj Emptyset Rn and Eriksson, Mikael and Petrilli, Antonio Sérgio and Bleyer, Archie and Thomas, David M}}, issn = {{1527-7755}}, language = {{eng}}, number = {{18}}, pages = {{130--2303}}, publisher = {{American Society of Clinical Oncology}}, series = {{Journal of Clinical Oncology}}, title = {{Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis.}}, url = {{http://dx.doi.org/10.1200/JCO.2012.43.8598}}, doi = {{10.1200/JCO.2012.43.8598}}, volume = {{31}}, year = {{2013}}, }